Anatara Secures European Patent for GaRP Product

Anatara Lifesciences Ltd (AU:ANR) has released an update.

Anatara Lifesciences has announced the granting of a European patent for its GaRP product, aimed at treating gastrointestinal disorders, including IBS, with protection extending until March 2039. This patent covers 19 European countries plus the UK and taps into a US$8 billion market opportunity for non-prescription digestive health products in the US alone. The newly patented GaRP product is designed to modify disease by restoring the gastrointestinal tract lining and microbiome homeostasis, positioning Anatara at the forefront of addressing a significant unmet medical need.

For further insights into AU:ANR stock, check out TipRanks’ Stock Analysis page.